bosentan anhydrous has been researched along with ro 47-8634 in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cruciani, G; Goracci, L; Lepri, S; Valeri, A | 1 |
| Bolli, MH; Boss, C; Gatfield, J | 1 |
| Birnboeck, H; Eggers, H; Hopfgartner, G; Jonkman, JH; Meyer, J; Schmitt, R; van Marle, S; Viischer, HW; Weber, C | 1 |
| Auge, D; Fahrmayr, C; Fromm, M; König, J; Mieth, M; Münch, K; Pfeifer, T; Segrestaa, J; Treiber, A | 1 |
| Imawaka, H; Kaneko, N; Matsunaga, N; Nakanishi, T; Nunoya, K; Staub, AY; Tamai, I | 1 |
1 review(s) available for bosentan anhydrous and ro 47-8634
| Article | Year |
|---|---|
From bosentan (Tracleer®) to macitentan (Opsumit®): The medicinal chemistry perspective.
Topics: Bosentan; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; Humans; Molecular Structure; Pyrimidines; Receptors, Endothelin; Structure-Activity Relationship; Sulfonamides | 2016 |
1 trial(s) available for bosentan anhydrous and ro 47-8634
| Article | Year |
|---|---|
Multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers.
Topics: Administration, Oral; Antihypertensive Agents; Area Under Curve; Blood Pressure; Bosentan; Diastole; Dose-Response Relationship, Drug; Double-Blind Method; Endothelin Receptor Antagonists; Gastrointestinal Diseases; Headache; Humans; Male; Metabolic Clearance Rate; Pyrimidines; Sulfonamides; Systole | 1999 |
3 other study(ies) available for bosentan anhydrous and ro 47-8634
| Article | Year |
|---|---|
Metabolism study and biological evaluation of bosentan derivatives.
Topics: Animals; Bosentan; Cell Line, Tumor; Cell Survival; CHO Cells; Cricetinae; Cricetulus; Cytochrome P-450 CYP2C9; Endothelin Receptor Antagonists; Models, Molecular; Protein Conformation; Receptors, Endothelin; Sulfonamides | 2016 |
Phase I and II metabolism and MRP2-mediated export of bosentan in a MDCKII-OATP1B1-CYP3A4-UGT1A1-MRP2 quadruple-transfected cell line.
Topics: Animals; Antihypertensive Agents; Biological Transport; Bosentan; Chromatography, High Pressure Liquid; Chromatography, Liquid; Cytochrome P-450 CYP3A; Dogs; Endothelin Receptor Antagonists; Glucuronides; Glucuronosyltransferase; Humans; Liver-Specific Organic Anion Transporter 1; Madin Darby Canine Kidney Cells; Mass Spectrometry; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Organic Anion Transporters; Pyrimidines; Sulfonamides; Transfection | 2013 |
Analysis of the Metabolic Pathway of Bosentan and of the Cytotoxicity of Bosentan Metabolites Based on a Quantitative Modeling of Metabolism and Transport in Sandwich-Cultured Human Hepatocytes.
Topics: Biological Transport; Biotransformation; Bosentan; Cell Culture Techniques; Cell Survival; Cells, Cultured; Chemical and Drug Induced Liver Injury; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2C9 Inhibitors; Endothelin Receptor Antagonists; Female; Hepatocytes; Humans; Hydroxylation; Kinetics; Male; Microsomes, Liver; Models, Biological; Pyrimidines; Sulfonamides | 2016 |